Riskpilot← Back to searchSign inGet full accessACUPHARMA ApS
APSActiveCVR 10072956Kong Haralds Vej 4Wholesale of other food · NACE 4638Est. 20012 employeeswww.acupharma.dk
Revenue 2025
DKK 1,2M
+89% vs 2024
EBITDA margin
29.6%
+439% vs 2024
Equity ratio
-5.1%
Financial strength
Net profit 2025
DKK 288K
+211% vs 2024
| Revenue | DKK 1,2M | +89% |
| EBITDA | DKK 340K | +439% |
| Net profit | DKK 288K | +211% |
| Total assets | DKK 2,2M | +18% |
| Equity | DKK -109K | +72% |
| Employees | 2 | — |
Legal name
ACUPHARMA ApS
CVR number
10072956
Legal form
Anpartsselskab
NACE code
4638 · Wholesale of other food
Founded
1. april 2001
Share capital
DKK 300.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af 2 direktører i forening.
Company purpose
Selskabets formål er at drive handel med urter og helsekostprodukter.
Address
Kong Haralds Vej 4
Phone
+4570228838
Email
jeanne@acupharma.dk
Website
www.acupharma.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 365 | 574 | 1.442 | 322 | 1.109 | 1.513 | 1.724 | 1.684 | 1.368 | 1.185 | 778 | 1.128 | 610 | 1.151 |
| Staff expenses | -587 | -548 | -547 | -628 | -962 | -1.246 | -1.479 | -1.316 | -1.354 | -908 | -921 | -724 | -815 | -811 |
| EBITDA | -223 | 26 | 895 | -305 | 147 | 268 | 245 | 369 | 13 | 277 | -206 | 404 | -100 | 340 |
| Depreciation & amort. | 48 | -31 | -52 | -60 | -71 | -79 | -132 | -186 | -185 | -174 | -111 | -105 | 52 | -55 |
| EBIT | -271 | -6 | 842 | -366 | 76 | 189 | 112 | 183 | -172 | 103 | -318 | 300 | -153 | 285 |
| Net financials | -30 | -44 | -103 | -98 | -73 | -85 | -101 | -139 | -128 | -94 | -102 | -146 | -106 | -78 |
| Profit before tax | -301 | -50 | 739 | -464 | 3 | 104 | 12 | 44 | -299 | 8 | -420 | 153 | -259 | 207 |
| Tax | -74 | -10 | 188 | -104 | 3 | 24 | 7 | 11 | -65 | 2 | 30 | -0 | -0 | -80 |
| Net profit | -227 | -39 | 551 | -360 | 0 | 80 | 5 | 33 | -235 | 6 | -450 | 153 | -259 | 288 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.555 | 1.580 | 2.545 | 1.625 | 2.092 | 2.643 | 3.258 | 3.292 | 2.550 | 2.397 | 2.011 | 2.103 | 1.820 | 2.152 |
| Equity | 261 | 222 | 773 | 68 | 68 | 149 | 154 | 387 | 152 | 158 | -291 | -138 | -397 | -109 |
| Long-term debt | 0 | 0 | 121 | 223 | 168 | 83 | 319 | 83 | 24 | 24 | 25 | 26 | 26 | 28 |
| Short-term debt | 1.294 | 1.358 | 1.583 | 1.320 | 1.846 | 2.396 | 2.764 | 2.790 | 2.374 | 2.215 | 2.277 | 2.216 | 2.191 | 2.233 |
| Total debt | 1.294 | 1.358 | 1.704 | 1.543 | 2.014 | 2.479 | 3.083 | 2.873 | 2.398 | 2.239 | 2.302 | 2.242 | 2.216 | 2.261 |
EBITDA margin
29.6%
This company
15.8%
Market median
+87% vs market
20122025
Equity ratio
-5.1%
This company
38.2%
Market median
-113% vs market
20122025
Return on equity
28757200.0%
This company
18.4%
Market median
+156289030% vs market
20122025
Net profit margin
25.0%
This company
8.1%
Market median
+209% vs market
20122025
Asset turnover
0.53×
This company
1.12×
Market median
-53% vs market
20122025
Debt / equity
20.69×
This company
0.62×
Market median
-3237% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-10-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2013-10-01 – 2014-09-30
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-09-30
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CU Management | Management | 2007 | — | — |
HS Founder | Founder | 2001 | — | — |
JH Management | Management | 2001 | — | — |
SE Founder | Founder | 2001 | — | — |
EJ Founder | Founder | 2001 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2005 | — | — | |
| Board of Directors | 2001 | — | — | |
| Board of Directors | 2001 | — | — | |
| Board of Directors | 2004 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
SKIVE & HELSTED A/S | Company | 100.0% | 100.0% | 2005 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SKIVE & HELSTED A/S
ACUPHARMA ApS Board members of ACUPHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christina Uekermann Skive | Management | 0 companies |
| Henrik Steen Jensen | Founder | 0 companies |
| Jeanne Helsted | Management | 0 companies |
| Steffen Ebdrup | Founder | 0 companies |
| Erik Jensen | Founder | 0 companies |
| Thomas Fog Helsted | Board of Directors | 0 companies |
| Søren Skive | Board of Directors | 0 companies |
| Michael Vinther | Board of Directors | 0 companies |
| John Helsted-Sørensen | Board of Directors | 0 companies |
| Christian Bendik Elmer | Board of Directors | 0 companies |